EXELIXIS, INC.

Exelixis, Inc. is an oncology-focused biotechnology company that discovers, develops, and commercializes targeted medicines for various forms of cancer. Its commercial portfolio features cabozantinib formulations, primarily marketed as CABOMETYX tablets and COMETRIQ capsules, alongside cobimetinib (COTELLIC) and esaxerenone (MINNEBRO). The company focuses on developing small molecules and biotherapeutics, such as antibody-drug conjugates, to treat indications including advanced renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumors. Its offerings serve physicians, healthcare providers, and cancer patients, while its clinical pipeline features investigational candidates like zanzalintinib across multiple oncology settings.

The company markets its products in the United States and distributes cabozantinib internationally across 68 other countries through regional collaboration partners, including Ipsen outside the U.S. and Japan, and Takeda within Japan. Regulatory approvals span major geographic markets such as the European Economic Area, the United Kingdom, Japan, Canada, Brazil, Taiwan, South Korea, Australia, and Hong Kong. The provided text does not state the company's headquarters location.

Summary of the business section of Exelixis's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 1,077 employees, representing a 6.10% decrease in our employee workforce as compared to December 31, 2024.”